ELISA Kit for Plasminogen Activator Inhibitor 1 (PAI1)

SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor

Specificity

This assay has high sensitivity and excellent specificity for detection of Plasminogen Activator Inhibitor 1 (PAI1).
No significant cross-reactivity or interference between Plasminogen Activator Inhibitor 1 (PAI1) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Plasminogen Activator Inhibitor 1 (PAI1) and the recovery rates were calculated by comparing the measured value to the expected amount of Plasminogen Activator Inhibitor 1 (PAI1) in samples.

Matrix Recovery range (%) Average(%)
sodium citrate plasma(n=5) 84-102 95

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Plasminogen Activator Inhibitor 1 (PAI1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Plasminogen Activator Inhibitor 1 (PAI1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Plasminogen Activator Inhibitor 1 (PAI1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
sodium citrate plasma(n=5) 83-93% 79-89% 92-104% 78-96%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Breast Cancer Research and Treatment Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice SpringerLink: f3w831267267p277
Clin Appl Thromb Hemost. Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency? Pubmed: 24203351
Molecular Nutrition & Food Research Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptors PubMed: 25546502
Archives of Physiology and Biochemistry Activation of cardiac renin–angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder Pubmed:26934364
Naunyn-Schmiedeberg's Archives of Pharmacology Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression pubmed:27447455
Environmental toxicology and pharmacology Combined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats. pubmed:28376377
Annals of Clinical & Laboratory Science Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatment pubmed:28249913
Pharmacological reports Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance are glucocorticoid-independent pubmed:28349880
Haematologica Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain Pubmed:29903766
Biomedicine & Pharmacotherapy Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cells Pubmed:29775893
Archives of Physical Medicine and Rehabilitation Impact of Regular Physical Activity on Adipocytokines and Cardiovascular Characteristics in Spinal Cord–Injured Subjects Pubmed:29548578
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPA532Ra01 Recombinant Plasminogen Activator Inhibitor 1 (PAI1) Positive Control; Immunogen; SDS-PAGE; WB.
PAA532Ra01 Polyclonal Antibody to Plasminogen Activator Inhibitor 1 (PAI1) WB; IHC; ICC; IP.
MAA532Ra21 Monoclonal Antibody to Plasminogen Activator Inhibitor 1 (PAI1) WB; IHC; ICC; IP.
SEA532Ra ELISA Kit for Plasminogen Activator Inhibitor 1 (PAI1) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA532Ra CLIA Kit for Plasminogen Activator Inhibitor 1 (PAI1) Chemiluminescent immunoassay for Antigen Detection.
KSA532Ra01 ELISA Kit DIY Materials for Plasminogen Activator Inhibitor 1 (PAI1) Main materials for "Do It (ELISA Kit) Yourself".